Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

No abstract is available for this paper.

• Publication year

  2005

• Venue

  International Archives of Allergy and Immunology

• Publication date

  2005-08-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1159/000087358PMID 16103688
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ADAM33 gene: confirming a gene without linkage

  2004cited by this paper
• Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells

  2004cited by this paper
• Vaccination with genetically engineered allergens prevents progression of allergic disease

  2004cited by this paper
• Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease.

  2004cited by this paper
• Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1

  2004cited by this paper
• Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity1

  2004cited by this paper
• Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.

  2003cited by this paper
• To respond or not to respond: T cells in allergic asthma

  2003cited by this paper
• Allergen‐specific immunotherapy with a monophosphoryl lipid A‐adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy‐induced blocking antibodies

  2003cited by this paper
• Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.

  2003cited by this paper
• 25. Immunotherapy of allergic disease.

  2003cited by this paper
• IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

  2003cited by this paper
• Dendritic-cell control of pathogen-driven T-cell polarization

  2003cited by this paper
• The future of antigen-specific immunotherapy of allergy

  2002cited by this paper
• Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System™

  2002cited by this paper
• Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild‐type in patients with allergic rhinitis

  2002cited by this paper
• Specific immunotherapy prevents increased levels of allergen‐specific IL‐4‐ and IL‐13‐producing cells during pollen season

  2001cited by this paper
• Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1

  2001cited by this paper
• IgG Fc receptors.

  2001cited by this paper
• Antigen-presenting cells in allergy.

  2001cited by this paper
• T Cell Epitope-Containing Hypoallergenic Recombinant Fragments of the Major Birch Pollen Allergen, Bet v 1, Induce Blocking Antibodies1

  2000cited by this paper
• Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild‐type by skin prick and intradermal testing: results obtained in a French population

  2000cited by this paper
• Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens.

  2000cited by this paper
• Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients.

  2000cited by this paper
• A molecular basis for T cell suppression by IL‐10: CD28‐associated IL‐10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3‐kinase binding

  2000cited by this paper
• Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy

  1999cited by this paper
• Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.

  1999cited by this paper
• Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.

  1998cited by this paper
• Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T‐cell clones specific for Phi p 1, a major grass pollen allergen

  1997cited by this paper
• Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

  1997cited by this paper
• Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5).

  1996cited by this paper
• Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures.

  1995cited by this paper
• Chemically modified antigen preferentially elicits induction of Th1- like cytokine synthesis patterns in vivo

  1993cited by this paper
• Number of interleukin‐4‐ and interferon‐γ‐secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation

  1993cited by this paper
• Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals

  1993cited by this paper
• Immunotherapy for allergic disease.

  1976cited by this paper
• The FASEB Journal express article 10.1096/fj.01-1012fje. Published online June 21, 2002.

  year unknowncited by this paper

• Tolerogenic Nano-/Microparticle Vaccines for Immunotherapy.

  2024cites this paper
• Allergen Immunotherapy: Current and Future Trends

  2022cites this paper
• Isolation of nanobodies with potential to reduce patients' IgE binding to Bet v 1

  2021cites this paper
• One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future.

  2021cites this paper
• Mucosal Vaccines for Allergy and Tolerance

  2020cites this paper
• Egg Allergy: Diagnosis and Immunotherapy

  2020cites this paper
• IgE and allergen‐specific immunotherapy‐induced IgG4 recognize similar epitopes of Bet v 1, the major allergen of birch pollen

  2017cites this paper
• Investigational new drugs for allergic rhinitis

  2017cites this paper
• Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract

  2017cites this paper
• Next generation immunotherapy for tree pollen allergies

  2017cites this paper
• Chinese Guideline on allergen immunotherapy for allergic rhinitis.

  2017cites this paper
• Allergen immunotherapy for birch pollen-allergic patients: recent advances.

  2016cites this paper
• Immune Responses to Allergens in Atopic Disease: Considerations for Bioinformatics

  2015cites this paper
• Folded or Not? Tracking Bet v 1 Conformation in Recombinant Allergen Preparations

  2015cites this paper
• Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy.

  2015cites this paper
• Suppression of dust mite allergy by mucosal delivery of a hypoallergenic derivative in a mouse model

  2015cites this paper
• Generation of a chimeric dust mite hypoallergen using DNA shuffling for application in allergen-specific immunotherapy.

  2014cites this paper
• Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy

  2014cites this paper
• Original Article Generation of a chimeric dust mite hypoallergen using DNA shuffling for application in allergen-specific immunotherapy

  2014cites this paper
• Recombinant house dust mite allergens.

  2014cites this paper
• New Directions in Immunotherapy

  2013cites this paper
• Allergen‐specific immunotherapy: from therapeutic vaccines to prophylactic approaches

  2012cites this paper
• ALLERGY TO PETS; MOLECULAR APPROACHES FOR IMPROVED DIAGNOSTICS AND VACCINATION

  2012cites this paper
• Immune regulation and modulation of allergy and inflammatory diseases

  2012cites this paper
• Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.

  2012cites this paper
• Recombinant allergens for allergen‐specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens

  2011cites this paper
• Clinical experience with recombinant molecules for allergy vaccination.

  2011cites this paper
• Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.

  2011cites this paper
• In Vitro Evolution of Allergy Vaccine Candidates, with Maintained Structure, but Reduced B Cell and T Cell Activation Capacity

  2011cites this paper
• In Search of a Vaccine for Mouse Allergy: Significant Reduction of Mus m 1 Allergenicity by Structure-Guided Single-Point Mutations

  2011cites this paper
• Proteomic analysis of the major birch allergen Bet v 1 predicts allergenicity for 15 birch species.

  2011cites this paper
• Nanovesicles from Malassezia sympodialis and Host Exosomes Induce Cytokine Responses – Novel Mechanisms for Host-Microbe Interactions in Atopic Eczema

  2011cites this paper
• Induction of allergen-specific tolerance via mucosal routes.

  2011cites this paper
• Recombinant allergens for specific immunotherapy.

  2011cites this paper
• Peptide and recombinant immunotherapy.

  2011cites this paper
• echanisms underlying allergy vaccination with recombinant hypoallergenic llergen derivatives

  2011cites this paper
• Clinical practice

  2011cites this paper
• Sublingual specific immunotherapy.

  2010cites this paper
• Tracking Antigen-Specific T-Cells during Clinical Tolerance Induction in Humans

  2010cites this paper
• Allergen-spezifische Immuntherapie bei Kindern und Jugendlichen

  2010cites this paper
• Recombinant Bet v 1 vaccine for treatment of allergy to birch pollen

  2010cites this paper
• Inhibition of CD23‐dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules

  2010cites this paper
• Engineering Allergy Vaccines: Approaches Towards Engineered Allergy Vaccines

  2010cites this paper
• Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial

  2010cites this paper
• Basic Aspects of Allergy and Hypersensitivity Reactions

  2009cites this paper
• Allergen-specific immunotherapy of allergy and asthma: current and future trends

  2009cites this paper
• Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination

  2009cites this paper
• RECOMBINANT CAT AND MITE ALLERGENS AS TOOLS IN THE STUDY OF DIAGNOSIS AND TREATMENT OF ALLERGY

  2009cites this paper
• Development of recombinant allergens for diagnosis and therapy.

  2009cites this paper
• Immunotherapy for Inhalant Allergens

  2009cites this paper
• Recombinant Allergens for Therapy and Prevention: Molecular Design and Delivery of Allergy Vaccines

  2009cites this paper
• Of cats and men: immunodominance and the role of HLA‐DP/DQ

  2008cites this paper
• Review article: From allergen genes to new forms of allergy diagnosis and treatment

  2008cites this paper
• Novel treatment strategies and regulation of IgE-mediated allergic disease.

  2008cites this paper
• Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering.

  2008cites this paper
• Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives

  2008cites this paper
• Control and regulation of peripheral tolerance in allergic inflammatory disease: therapeutic consequences.

  2008cites this paper
• Design and modifications of allergens for improving specific immunotherapy.

  2008cites this paper
• Novel allergen preparations for use in allergen-specific immunotherapy

  2008cites this paper
• A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6

  2008cites this paper
• CC16 in allergy and allergic inflammation

  2008cites this paper
• Birch pollen allergy: molecular characterization and hypoallergenic products

  2008cites this paper
• Influence of Toll-like-receptor ligands on the dendritic cell-T cell interactions: therapeutic options for allergic diseases? Mini-review.

  2008cites this paper
• Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy.

  2008cites this paper
• Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.

  2008cites this paper
• Cross-Sensitization to Profilin ofPollen Profilin , Phl p 12 , for the Treatment GrassTail-to-Head Restructuring of Timothy A Hypoallergenic Vaccine Obtained

  2007cites this paper
• Specific immunotherapy in pollen allergy.

  2007cites this paper
• ImmunogenicityAllergenic Activity and Preserve Grass Pollen Allergen, Phl p 6, to Reduce Genetic Engineering of the Major Timothy

  2007cites this paper
• Les allergènes recombinants : leur apport à l’allergologie en 2006

  2007cites this paper
• Hyposensibilisierung: Für wen was? Zum Stellenwert der allergen-spezifischen Immuntherapie (ASIT) im Gesamtkonzept antiallergischer Therapieverfahren

  2007cites this paper
• Genetic Engineering of the Major Timothy Grass Pollen Allergen, Phl p 6, to Reduce Allergenic Activity and Preserve Immunogenicity1

  2007cites this paper
• Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: Destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines

  2007cites this paper
• Allergic rhinitis and its impact on asthma update: allergen immunotherapy.

  2007cites this paper
• Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area.

  2007cites this paper
• Allergy vaccines: dreams and reality

  2007cites this paper
• A Hypoallergenic Vaccine Obtained by Tail-to-Head Restructuring of Timothy Grass Pollen Profilin, Phl p 12, for the Treatment of Cross-Sensitization to Profilin1

  2007cites this paper
• Recombinant allergens for immunotherapy.

  2007cites this paper
• Molecular approaches for new vaccines against allergy

  2006cites this paper
• Hypoallergenic fragment of Par j 2 increases functional expression of Toll‐like receptors in atopic children

  2006cites this paper
• Immunoregulation by targeting T cells in the treatment of allergy and asthma.

  2006cites this paper
• Immunological mechanisms of allergen-specific immunotherapy

  2006cites this paper
• Future of allergen-specific immunotherapy: better understanding of the mechanisms, novel treatments, and long-term cure.

  2006cites this paper
• Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines.

  2006cites this paper
• Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines.

  2006cites this paper
• Allergy and hypersensitivity: mechanisms of allergic disease.

  2006cites this paper
• Hypoallergens for Allergen-specific Immunotherapy by Directed Molecular Evolution of Mite Group 2 Allergens*

  2006cites this paper
• Strategies for recombinant allergen vaccines and fruitful results from first clinical studies.

  2006cites this paper
• Novel vaccines and adjuvants for allergen-specific immunotherapy.

  2006cites this paper
• Sublingual immunotherapy of allergic diseases

  2006cites this paper
• Mechanisms of allergen specific immunotherapy – T‐cell tolerance and more

  2006cites this paper
• Molecular design of allergy vaccines.

  2005cites this paper